| Indication |
Patent |
Preclinical |
Clinical |
| |
filed |
|
I |
II |
III |
DasKloster 1001-01
Idiopathic Pulmonary Fibrosis (IPF) |
|
|
|
|
|
DasKloster 1000-01
Pulmonary Arterial Hypertension (PAH) |
|
|
|
|
|
DasKloster 1000–02
Sarcoidosis |
|
|
|
|
|
DasKloster 1000–03
Idiopathic Pulmonary Fibrosis (IPF) |
|
|
|
|
|
DasKloster 1000–04
Acute Respiratory Distress Syndrome (ARDS) |
|
|
|
|
|
DasKloster 0138–01
Methicillin-Resistant Staphylococcus Aureus in Cystic Fibrosis |
|
|
|
|
|
DasKloster 0247–01
Chronic Thromboembolic Pulmonary Hypertension |
|
|
|
|
|
DasKloster 0182–01
Sarcoidosis |
|
|
|
|
|
DasKloster 0210–01
Chronic Beryllium Disease |
|
|
|
|
|
DasKloster 0274–01
Pseudomonas Aeruginosa in Cystic Fibrosis |
|
|
|
|
|
DasKloster 0249–01
Drug-Resistant Tuberculosis |
|
|
|
|
|
12 Medicinal Product Candidate
Target not disclosed |
|
|
|
|
|
290 Medicinal Product Candidate
Target not disclosed |
|
|
|
|
|
2010
